In a welcome move, QuidelOrtho saw its Relative Strength Rating improve from 68 to 73 on Tuesday.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if QuidelOrtho can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
QuidelOrtho is within a buy zone after climbing above a 47.62 entry in a consolidation. Once a stock moves 5% or higher beyond the original entry, it's considered extended and out of buy range.
Earnings growth declined last quarter from 0% to -6%, but the top line rose from -4% to -2%.
QuidelOrtho earns the No. 70 rank among its peers in the Medical-Products industry group. Globus Medical, Pro-Dex and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
